Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Fleeman, N Bagust, A Boland, A Dickson, R Dundar, Y Moonan, M Oyee, J Blundell, M Davis, H Armstrong, Anne C
Fleeman, N
Bagust, A
Boland, A
Dickson, R
Dundar, Y
Moonan, M
Oyee, J
Blundell, M
Davis, H
Armstrong, Anne C
Citations
Altmetric:
Abstract
Breast cancer is the uncontrolled, abnormal growth of malignant breast tissue affecting predominantly women. Metastatic breast cancer (mBC) is an advanced stage of the disease when the disease has spread beyond the original organ. Hormone receptor status and human epidermal growth factor 2 (HER2) status are two predictive factors that are taken into consideration when estimating the prognosis of patients with breast cancer.
Description
Date
2011
Publisher
Collections
Keywords
Type
Article
Citation
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. 2011, 15 (42):1-93, iii-iv Health Technol Assess